2016
Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).
Santin A, Moore K, Gunderson C, Gowen K, Fabrizio D, Frampton G, Vergilio J, Suh J, Gay L, Ramkissoon S, Ali S, Miller V, Stephens P, Ross J, Sun J, Elvin J. Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). Journal Of Clinical Oncology 2016, 34: 5591-5591. DOI: 10.1200/jco.2016.34.15_suppl.5591.Peer-Reviewed Original Research
2008
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole
Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. American Journal Of Obstetrics And Gynecology 2008, 199: e7-e10. PMID: 18550023, DOI: 10.1016/j.ajog.2008.04.012.Peer-Reviewed Original Research
1999
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Santin A, Hermonat P, Ravaggi A, Pecorelli S, Cannon M, Parham G. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics And Gynecology 1999, 94: 78-82. PMID: 10389722, DOI: 10.1016/s0029-7844(99)00282-3.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorSquamous cell carcinomaEndothelial growth factorVascular endothelial growth factor (VEGF) secretionSquamous cell linesUterine cervixCell carcinomaGrowth factor secretionGrowth factorFactor secretionCell linesSensitive enzyme-linked immunosorbentSignificant differencesEnzyme-linked immunosorbentCervical carcinoma cell linesImmunosuppressive cytokinesHistologic typeCervical cancerCarcinoma cell linesCervical tumorsBiologic behaviorHematogenous metastasisAdenocarcinomaCervixRadiation treatmentSecretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix
SANTIN A, HERMONAT P, RAVAGGI A, PECORELLI S, CANNON M, PARHAM G. Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Obstetrics And Gynecology 1999, 94: 78-82. DOI: 10.1097/00006250-199907000-00015.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorSquamous cell carcinomaEndothelial growth factorVascular endothelial growth factor (VEGF) secretionSquamous cell linesUterine cervixCell carcinomaGrowth factor secretionGrowth factorFactor secretionCell linesSensitive enzyme-linked immunosorbentSignificant differencesEnzyme-linked immunosorbentCervical carcinoma cell linesImmunosuppressive cytokinesHistologic typeCervical cancerCarcinoma cell linesCervical tumorsBiologic behaviorHematogenous metastasisAdenocarcinomaCervixRadiation treatment
1997
Differential Transforming Growth Factor-β Secretion in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix
Santin A, Hermonat P, Hiserodt J, Fruehauf J, Schranz V, Barclay D, Pecorelli S, Parham G. Differential Transforming Growth Factor-β Secretion in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Gynecologic Oncology 1997, 64: 477-480. PMID: 9062154, DOI: 10.1006/gyno.1996.4579.Peer-Reviewed Original Research